| Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2 … JPH Machiels, RT Reilly, LA Emens, AM Ercolini, RY Lei, D Weintraub, ... Cancer research 61 (9), 3689-3697, 2001 | 552 | 2001 |
| Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response AM Ercolini, BH Ladle, EA Manning, LW Pfannenstiel, TD Armstrong, ... The Journal of experimental medicine 201 (10), 1591-1602, 2005 | 480 | 2005 |
| HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice RT Reilly, MBC Gottlieb, AM Ercolini, JPH Machiels, CE Kane, FI Okoye, ... Cancer research 60 (13), 3569-3576, 2000 | 301 | 2000 |
| The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors RT Reilly, JPH Machiels, LA Emens, AM Ercolini, FI Okoye, RY Lei, ... Cancer Research 61 (3), 880-883, 2001 | 204 | 2001 |
| OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen S Murata, BH Ladle, PS Kim, ER Lutz, ME Wolpoe, SE Ivie, HM Smith, ... The Journal of Immunology 176 (2), 974-983, 2006 | 121 | 2006 |
| Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice AM Ercolini, JPH Machiels, YC Chen, JE Slansky, M Giedlen, RT Reilly, ... The journal of Immunology 170 (8), 4273-4280, 2003 | 121 | 2003 |
| HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T … ME Wolpoe, ER Lutz, AM Ercolini, S Murata, SE Ivie, ES Garrett, ... The Journal of Immunology 171 (4), 2161-2169, 2003 | 120 | 2003 |
| Chemotherapy: friend or foe to cancer vaccines? LA Emens, JP Machiels, RT Reilly, EM Jaffee Current Opinion in Molecular Therapeutics 3 (1), 77-84, 2001 | 112 | 2001 |
| Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity LA Emens, RT Reilly, EM Jaffee Endocrine-related cancer 12 (1), 1-17, 2005 | 105 | 2005 |
| OX40 costimulation can abrogate Foxp3+ regulatory T cell‐mediated suppression of antitumor immunity N Kitamura, S Murata, T Ueki, E Mekata, RT Reilly, EM Jaffee, T Tani International journal of cancer 125 (3), 630-638, 2009 | 99 | 2009 |
| Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs PS Kim, TD Armstrong, H Song, ME Wolpoe, V Weiss, EA Manning, ... The Journal of clinical investigation 118 (5), 1700-1711, 2008 | 98 | 2008 |
| Ductal access for prevention and therapy of mammary tumors S Murata, SL Kominsky, M Vali, Z Zhang, E Garrett-Mayer, D Korz, D Huso, ... Cancer research 66 (2), 638-645, 2006 | 97 | 2006 |
| Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities NK Dakappagari, KD Lute, S Rawale, JT Steele, SD Allen, G Phillips, ... Journal of Biological Chemistry 280 (1), 54-63, 2005 | 86 | 2005 |
| Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1 AA Higazi, A Mazar, J Wang, R Reilly, J Henkin, D Kniss, D Cines | 86 | 1996 |
| 213Bi (α-Emitter)–Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model H Song, K Shahverdi, DL Huso, C Esaias, J Fox, A Liedy, Z Zhang, ... Cancer research 68 (10), 3873-3880, 2008 | 60 | 2008 |
| Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? RT Reilly, LA Emens, EM Jaffee Current opinion in investigational drugs (London, England: 2000) 2 (1), 133-135, 2001 | 59 | 2001 |
| Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesis M Ren, RT Reilly, N Sacchi Anticancer research 24 (5A), 2879-2884, 2004 | 57 | 2004 |
| A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with … LA Emens, D Armstrong, B Biedrzycki, N Davidson, J Davis-Sproul, ... Human gene therapy 15 (3), 313-337, 2004 | 45 | 2004 |
| An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer H Song, K Shahverdi, DL Huso, Y Wang, JJ Fox, RF Hobbs, B Gimi, ... Clinical Cancer Research 14 (19), 6116-6124, 2008 | 41 | 2008 |
| Soluble human urokinase receptor is composed of two active units AAR Higazi, A Mazar, J Wang, N Quan, R Griffin, R Reilly, J Henkin, ... Journal of Biological Chemistry 272 (8), 5348-5353, 1997 | 38 | 1997 |
